ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Study limitation reported by the research below: “Aβ42/40 and GFAP were only available in roughly 56% of participants in both cohorts; missing values were median-imputed from training data, and the complete-panel sensitivity analysis showed a different Aβ prevalence profile (55.7% vs. 87.1%), so imputation effects cannot be fully ruled out.”

Papers